| Literature DB >> 19787071 |
Tiffany J Morris1, Mark Vickers, Peter Gluckman, Stewart Gilmour, Nabeel Affara.
Abstract
A link has been established between prenatal nutrition and the development of metabolic and cardiovascular diseases later in life, a process referred to as developmental programming. It has been suggested that the trajectory of development is shifted by alterations in the maternal nutritional state leading to changes in developmental plasticity, in part underpinned by epigenetic changes in gene regulation. However, to date, only candidate gene approaches have been used to assess expression and molecular changes in the offspring of maternally undernourished animals. Furthermore, most work has focused on animals at an age where the programmed phenotype is already manifest and little is known about changes in gene expression in the offspring prior to development of obesity and related metabolic disorders. Gene expression profiles of liver, retroperitoneal white adipose fat, and biceps femoris skeletal muscle tissue from young adult male rats (55 days old) in which nutritional status had been manipulated in utero by maternal undernutrition (UN) were compared to the profiles of offspring of ad libitum fed mothers serving as the control group (AD) (8 offspring/group). The expression profiles were determined using the Illumina RatRef-12 BeadChip. No significant changes in expression were identified for skeletal muscle or white adipose tissue. However, studies of liver tissue showed 249 differentially expressed genes (143 up regulated, 106 down regulated). Although the animals at day 55 have yet to develop obesity they already show biochemical abnormalities and by day 110 express a phenotype characterized by increased adiposity and altered insulin sensitivity. An analysis of pathways affected suggests that intrauterine programming of UN animals to favor fat as an energy source results in mitochondrial dysfunction which initially affects the postnatal hepatic function and subsequently, via the resultant metabolic changes in other organs leads to the evolution of a phenotype similar to that of the metabolic syndrome.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19787071 PMCID: PMC2749934 DOI: 10.1371/journal.pone.0007271
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1qRT-PCR for Microarray Verification.
QRT-PCR for the two treatments was run in triplicate with cyclophilin as a control. The ΔΔCT values are shown for each gene along with error bars for standard error. (A) Seven genes were chosen from the 249 significantly differentially expressed genes on the Illumina microarray. The RNA from the 8 biological replicates was pooled for each of the two treatment groups. In Table 2, the ΔΔCT values have been converted into a fold change for comparison to the array results. (B) Five Previously Published Candidate Genes from Lillycrop et al. [11] were analyzed be qRT-PCR. Each of the eight individual samples was run in triplicate (24 data points for each treatment group). Due to the large number of data points, the error bars are very small and difficult to see.
Phenotype data, day 110 male offspring.
| AD mean | UN mean | Adjusted p-value | |
| Body weight (grams) | 511 | 489 | NS |
| Body length (mm) | 238 | 218 | 0.05 |
| Total Fat (%) | 27.8 | 35.6 | 0.05 |
| Fat pad weight (% of body weight) | 1.45 | 2.14 | 0.05 |
| Leptin (ng/ml) | 9.6 | 22.5 | 0.005 |
| Insulin (ng/ml) | 0.260 | 0.502 | 0.001 |
| C-Peptide (pg/ml) | 466 | 729 | 0.05 |
| Plasma glucose (mmol/l) | 7.0 | 7.2 | NS |
| Free Fatty Acids (mmol/l) | 0.86 | 0.99 | NS |
| Liver weight (% body weight) | 2.92 | 2.78 | NS |
| IGF-1 (ng/ml) | 1236 | 1145 | NS |
Phenotypic measurements relevant to metabolic syndrome measured for each of the eight animals in each treatment group at day 110. The p-value was calculated with a t-test and an FDR correction. NS = not significant.
Phenotype data, day 55 offspring.
| AD mean | UN mean | Adjusted p-value | |
| Body weight (grams) | 282.38 | 234.50 | 0.001 |
| Body length (mm) | 203.63 | 192.63 | 0.005 |
| Liver weight (% body weight) | 3.65 | 3.02 | 0.014 |
| Spleen weight (% body weight) | 0.32 | 0.27 | NS |
| Heart weight (% body weight) | 0.36 | 0.71 | NS |
| Fat pad weight (% of body weight) | 0.80 | 0.59 | 0.039 |
| Plasma glucose (mmol/l) | 6.24 | 6.67 | NS |
| Urea (mmol/l) | 4.76 | 6.18 | 0.010 |
| Free Fatty Acids (mmol/l) | 0.79 | 0.68 | NS |
| Glycerol (mmol/l) | 0.21 | 0.19 | NS |
| Total Protein (g/DL) | 5.45 | 5.39 | NS |
| Lipase (U/l) | 9.10 | 9.06 | NS |
| C-Peptide (pg/ml) | 132.18 | 162.85 | NS |
| Triglycerides (mmol/l) | 0.78 | 0.77 | NS |
| IGF-1 (ng/ml) | 1221.50 | 1277.63 | NS |
| Creatinine (mmol/l) | 20.15 | 23.64 | NS |
| Insulin (ng/ml) | 0.33 | 0.53 | NS |
| Total Fat (%) | 24.09 | 23.66 | NS |
| LDL (mmol/l) | 0.27 | 0.46 | 0.006 |
| HDL (mmol/l) | 1.27 | 1.34 | NS |
| LDL∶HDL ratio | 0.21 | 0.35 | 0.003 |
Phenotypic measurements relevant to metabolic syndrome measured for each of the eight animals in each treatment group at day 55. The p-value was calculated with a t-test and an FDR correction. NS = not significant.
Fold Change Values Comparing Microarray and QRT-PCR.
| Gene Symbol | Genbank Accession Number | Microarray Expression (Fold Change) | QRT-PCR Expression (Fold Change) |
| ADRA1B | NM_016991.2 | 0.735 | 1.932 |
| DGAT2 | XM_574498.1 | 0.764 | 0.494 |
| FABP7 | NM_030832.1 | 1.381 | 1.682 |
| GYS2 | NM_013089.1 | 1.541 | 1.606 |
| IGFBP2 | NM_013122.1 | 2.144 | 2.732 |
| Zfand2a | NM_001008363.1 | 1.492 | 2.549 |
| RPB1 | XM_230637.3 | 1.631 | 1.217 |
Fold change for the QRT-PCR data and the Illumina expression data is compared for each of the seven genes from the Illumina arrays that were analyzed by QRT-PCR. Fold changes for the RT-PCR reflect directly the ΔΔCt values between the two groups after normalization.
Analysis of gene function associated with differentially expressed genes.
| METABOLIC AREA | SYMBOL | GENE IDENTIFICATION | % ΔEXP | FUNCTION |
| Carbohydrate and Glucose metabolism | Gys2 | glycogen synthase | 54 | stimulation of glucose storage |
| Gbe1 | glucan 1,4α branching enzyme | −38 | impairment of glycogen storage | |
| Pgm1 | phosphoglucomutase | −14 | increases glycogenesis over glycolysis | |
| Tpi | triose phosphate isomerase | −28 | attenuation of glycolysis and energy production | |
| Gcgr | glucagon receptor | −15 | attenuation of glycogenolysis | |
| Trib3 | Tribbles homolog 3 | 11 | impairment of insulin/IGF signaling at Akt | |
| Ptprb | protein tyrosine phosphatase receptor type B | 25 | impairment of insulin/IGF signaling at Atk | |
| Rbp1 | Retinol binding protein 1 | 63 | impairment of insulin/IGF signalling at PI3Kinase | |
| Igfbp2 | insulin-like growth factor binding protein 2 | 114 | impaired IGD binding to receptor | |
| p49/STRAP | SRF-dependent transcription regulation associated protein | 10 | interference with GLUT4 biosynthesis and recycling | |
| TRIP3 | thyroid hormone interactor protein 3 (TRIP3) | 6 | activator of NHF-4α dependent effects on glucose metabolism | |
| Dhtkd1 | dehydrogenase E1 and transketolase | 30 | catalyses αketoglutarate→succinylCoA in TCA | |
| Fat and Lipid Metabolism | Crat | carnitine acyltransferase | 18 | increased transport of acylCoA from cytosol to mitochondrion |
| Tmhle | trimethyllysine hydroxylase | −12 | biosynthesis of carnitine | |
| Dgat2 | diacylglycerol acyltransferase | −12 | decreased synthesis of triglycerides | |
| Fabp7 | fatty acid binding protein 7 | 40 | increased uptake and intracellular transport of fatty acids | |
| Scap | SREBP cleavage activating protein (Scap) | 20 | increased hepatic lipid synthesis | |
| Igfbp2 | IGF binding protein 2 | 114 | protection against obesity and insulin resistance | |
| Ptprb | protein tyrosine phosphatase receptor type B | 25 | contributes to hepatic leptin resistance | |
| Stard5 | steroidogenic acute regulatory protein | −12 | intracellular cholesterol transport | |
| Cyp4f4 | cytochrome P450 | −28 | involved in cholesterol, steroid and leukotriene synthesis | |
| Cyp4f6 | cytochrome P450 | −18 | involved in cholesterol, steroid and leukotriene synthesis | |
| Atp8b1 | ATPase class II type 8B | 16.5 | phosphatidyl serine and threonine transferase | |
| Cidea | cell death inducing DNA fragmentation factor α-like effector | −28 | shown to regulate energy expenditure and lipolysis | |
| Ebp | phenyalkylamine Ca2+ antagonist (emopamil) binding protein | 20 | isomerase involved in the conversion of lanosterol to cholesterol | |
| Amino Acid Metabolism | Got2 | glutamate/oxaloacetate transaminase | −10 | aspartate aminotransferase in aa catabolism and malate shuttle |
| Dhtkd1 | dehydrogenaseE1 and transketolase domain containing 1 | −30 | 2-ketoglutarate dehydrogenase activity | |
| Hpd | 4-hydroxyphenylpyruvate oxidase | 16 | participates in tyrosine catabolism | |
| Haao | 3-hydroxyanthanillate dioxygenase | −12 | participates in tryptophan catabolism | |
| Protein turnover | Zfand2a | arsenite inducible RNA associated protein | 40 | adapts proteosome to counteract stress-induced proteotoxicity |
| Tmprss6 | transmembrane serine protease 6 | −15 | ||
| Capn7 | calpain 7 | −15 | ||
| Cpn2 | carboxypeptidase N83 | −58 | ||
| Capsn1 | calpain small subunit 1 | −21 | ||
| Fam108b1 | Cgi67 serine protease | −2.8 | ||
| Serpinb6b | serine(or cysteine) peptidase inhibitor,clade B, member 6 | 25 | ||
| Cand1 | cullin associated/neddylation dissociated 1 | 15 | involved in targeted protein proteosomal degradation | |
| Dcun1d5 | defective in cullin neddylation1, domain 5 (DCN1) | 13 | involved in targeted protein proteosomal degradation | |
| Txndc12 | Thioredoxin domain containing 12 (Txndc12) | 20.6 | protein refolding, defense against oxidative stress | |
| Ubfd1 | ubiquitin family domain containing 1 (Ubfd1) | 14 | involved in targeted protein proteosomal degradation | |
| Eif4a1 | translation initiation factor 4A1 | 20 | ||
| Ribosomes | Rpl7a | ribosomal protein L7a (mitochondrial) | 24 | |
| Rps19 | ribosomal protein S19 | 22 | ||
| Rpl14 | ribosomal protein L14 (mitochondrial) | 20 | ||
| Rps26 | ribosomal protein S26 (mitochondrial) | 19 | ||
| Rp23a | ribosomal protein 23a (mitochondrial) | 19 | ||
| Rpl27a | ribosomal protein 27a (mitochondrial) | 18 | ||
| Rpl21 | ribosomal proetin L21(mitochondrial) | 17 | ||
| Rpl31 | ribosomal protein L31 | 17 | ||
| Rpl39 | ribosomal protein L39 | 15 | ||
| Rpl6 | ribosomal protein L6 | 14 | ||
| Rps17 | ribosomal protein S17 (mitochondrial) | 14 | ||
| Rpl24 | ribosomal protetin L24 | 14 | ||
| Rpl13 | ribosomal protein L13 (mitochondrial) | 7 | ||
| NPG1 | autoantigen NPG1 | 16 | required for the maturation/nuclear export of pre-ribosomes | |
| Bxdc1 | brix domain containing 1 | 11 | control of ribosome biogenesis | |
| Crlz1 | charged amino acid leucine zipper 1 | 26 | required for 18s rRNA processing | |
| Rrp15 | ribosomal protein processing homolog 15 (Rrp15) | 17 | ||
| Cebpz | CCAAT/enhancer binding protein zeta | 17.4 | Ribosomal RNA processing | |
| Apoptosis | Dnase1l3 | DNAse 1-like 3 | 40 | fragments DNA during apoptosis |
| Ppid | peptidyl prolyl isomerase D (Cyclophilin D) | 20 | anti-apoptotic. Blocks mitochondrial permeability | |
| Ei24 | etoposide induced 2.4 mRNA | 17 | may suppress cell growth by inducing apoptosis | |
| Prkch | protein kinase C eta | 14 | anti-apoptotic. Potent activator of Raf1 | |
| Sgpl1 | sphingosine phosphate lyase | 18 | apoptotic. Enhances stress-induced ceramide release | |
| Aatf | apoptosis antagonising factor | 13 | anti-apoptotic nuclear phosphoprotein transcription factor | |
| Cidea | cell death inducing DNA fragmentation factor α-like effector | −28 | apoptotic factor which induces DNA fragmentation | |
| SP16 | serpin 9b protease inhibitor | 27 | regulates apoptosis by inhibiting caspases 8 and 10 | |
| Mitochondrion and Electron Transport Chain | LOC499612 | NADH dehydrogenase (ubiquinone) complex unknown | −11 | uncharacterised component of electron transport chain |
| Ndufc2 | NADH dehydrogenase (ubiquinone) 1 complex unknown 2 | −12 | uncharacterised component of electron transport chain | |
| Ndufc6 | NADH dehydrogenase (ubiquinone) 1 beta subcomplex 6 | −16 | component of Complex I of electron transport chain | |
| Ndufa8 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 8 | −19 | component of Complex I of electron transport chain | |
| p45/STRAP | SRF-dependent transcription regulated associated factor | −10 | reported to interfere with Comlpex I assembly | |
| BC088177 - Qprt | quinolate phosphoribosyl transferase | −29 | participates in NAD biosynthesis | |
| Qprt | quinolate phosphoribosyl transferase | −15 | participates in NAD biosynthesis | |
| Atp5o | ATP synthase H ion transporting | −14 | part of the mitochondrial ATP synthesis complex | |
| Atpi | ATPase inhibitor | −12 | prevents ATP hydrolysis during electron flux | |
| Ppid | peptidyl prolyl isomerase D (Cyclophilin) | −20 | part of mitochondrial transition pore | |
| Tim14 | translocase complex subunit Tim14 | −29 | component of the mitochondrial protein import motor | |
| Haao | 3-hydroxyanthanillate dioxygenase | −12 | provides quinolate for NAD synthesis | |
| Transcription | Crem | cAMP responsive element modulator | 27 | PKA activation. Role in glucose and fat metabolism |
| Gtf2a2 | general transcription factor IIa 2 | 12.5 | part of the preinitiation transcription complex | |
| Gtf2hI | general transcription factor II H, polypeptide 1 | 3 | part of the preinitiation transcription complex | |
| MED21 | mediator complex subunit 21 | 11 | part of the RNA polymerase II transcription unit | |
| MED6 | mediator complex subunit 6 | 9.3 | part of the RNA polymerase II transcription unit | |
| Rbp1 | retinoic acid binding protein | 63 | RXR formation and PPAR activation | |
| DDX52 | DEAD box polypeptide 52 | 18.7 | ATP-dependent RNA helicase | |
| Ccdc12 | Ccdc coiled-coil domain containing 12 | 14 | involved in mRNA splicing |
Summarizes the interesting categories to emerge from analysis of gene functions (some of which emerged from DAVID and Ingenuity analyses) associated with the list of differentially expressed genes.
Figure 2Genes that Influence Glucose, Fat, and Energy Metabolism Pathways and IGF-1 and PI3K Signaling Pathways.
(A) Summarizes the interrelationships between pathways involved in glucose, fat, and energy metabolism and highlights differentially regulated genes that influence these pathways. (B) A summary of the genes that are altered in signaling through the IGF-1 and PI3K signaling pathways and their relevance to glucose and fat metabolism. Normal arrows indicate no change in gene expression; dashed arrows indicate down regulation; bold arrows indicate up-regulation.